-
2025-523286-23-00
9
Breast Cancer
-
2025-524181-26-00
4
relapsed/refractory multiple myeloma
-
2025-524297-42-00
5
CLTI defined as Rutherford category 4 or 5
-
2024-516527-13-00
11
2026-05-27
Kidney transplantation
-
2024-515181-14-00
5
2026-05-20
Patients with preoperative biliary stent treated by
pancreaticoduodene
-
2025-522878-36-00
5
2026-04-20
Chronic Spontaneous Urticaria
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2025-521293-34-00
4
2025-12-09
Moderate-to-severe hidradenitis suppurativa
-
2024-512029-10-00
5
2025-12-05
Intermediate risk, non-muscle invasive bladder cancer
-
2024-518006-40-00
5
2025-11-13
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2024-512753-24-00
5
2025-08-05
Acute Myeloid Leukemia (AML)
-
2024-518973-32-00
5
2025-07-03
Chronic Graft-Versus-Host Disease
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2023-507097-41-01
5
2025-03-20
Patients with limited-stage small cell lung cancer (LS-SCLC)
without
-
2024-513018-36-00
5
2025-03-06
Lung Diseases, Interstitial
-
2023-507853-13-00
4
2025-02-25
Ulcerative Colitis
-
2023-509482-20-00
4
2024-12-03
Solid Tumors
-
2024-514799-42-00
4
2024-11-05
IDIOPATHIC PULMONARY FIBROSIS